Alexion Pharmaceuticals (ALXN +4.3%) trades higher after its Q4 beat estimates across the board...

|About: Alexion Pharmaceuticals, Inc. (ALXN)|By:, SA News Editor

Alexion Pharmaceuticals (ALXN +4.3%) trades higher after its Q4 beat estimates across the board earlier today. Revenue jumped 45% Y/Y on higher overall net product sales, particularly in its blood disease drug Soliris with new PNH patients.